

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202331035649 A

(19) INDIA

(22) Date of filing of Application :23/05/2023

(43) Publication Date : 26/05/2023

(54) Title of the invention : EARLY DETECTION OF PARKINSON DISEASE BY IDENTIFICATION OF ALPHA-SYNUCLEIN OLIGOMER PROTEIN IN SALIVA

(51) International classification :A61K31/131
(86) International Application No :NA
Filing Date :NA
(87) International Publication No :NA
(61) Patent of Addition to Application Number :NA
Filing Date :NA
(62) Divisional to Application Number :NA
Filing Date :NA

(71)Name of Applicant :

1)Brainware University, Kolkata

Address of Applicant :398, Ramkrishnapur Rd, Near Jagadighata Market, Barasat, Kolkata, West Bengal 700125 -----

Name of Applicant : NA

Address of Applicant : NA

(72)Name of Inventor :

1)Dr. Animesh Dey

Address of Applicant :Assistant Professor, Department of Allied Health Sciences, Brainware University, 398, Ramkrishnapur Rd, near Jagadighata Market, Barasat, Kolkata, West Bengal, 700125 -

2)Dr. Sriparna De

Address of Applicant :Assistant Professor, Department of Allied Health Sciences, Brainware University, 398, Ramkrishnapur Rd, near Jagadighata Market, Barasat, Kolkata, West Bengal, 700125 -

(57) Abstract :

The present invention relates to a method and system for the early detection of Parkinsons disease by identifying the presence of alpha-synuclein oligomer protein in saliva samples. Parkinsons disease is a progressive neurodegenerative disorder characterized by the accumulation of abnormal protein aggregates in the brain. Early detection of Parkinsons disease is crucial for timely intervention and treatment. The proposed method utilizes advanced biochemical analysis techniques to accurately detect and quantify the alpha-synuclein oligomer protein in saliva samples. This non-invasive approach offers several advantages over traditional diagnostic methods, including convenience, accessibility, and cost-effectiveness. The invention enables proactive screening and identification of at-risk individuals, allowing for early interventions that may delay disease progression and improve patient outcomes. Additionally, the detection of alpha-synuclein oligomer protein in saliva samples may have broader implications for monitoring disease progression, evaluating treatment efficacy, and identifying potential biomarkers for novel therapeutic approaches. The proposed invention represents a significant advancement in Parkinsons disease diagnosis, offering a reliable and accessible tool for early detection and management of the disease. Accompanied Drawing [FIGS. 1-2]

No. of Pages : 22 No. of Claims : 10